

# SignalSilence® Beclin-1 siRNA II



✓ 10 µM in 300 µl (100 transfections)

Orders ■ 877-616-CELL (2355) orders@cellsignal.com  
Support ■ 877-678-TECH (8324) info@cellsignal.com  
Web ■ www.cellsignal.com

rev. 02/09/16

For Research Use Only. Not For Use In Diagnostic Procedures.

### Species Cross-Reactivity: H, (R)


**Description:** SignalSilence® Beclin-1 siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit Beclin-1 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

**Background:** Autophagy is a catabolic process for the autophagosomal-lysosomal degradation of proteins activated in response to nutrient deprivation and in neurodegenerative conditions (1). One of the proteins critical to this process is Beclin-1, the mammalian orthologue of the yeast autophagy protein Apg6/Vps30 (2). Beclin-1 can complement defects in yeast autophagy caused by loss of Apg6 and can also stimulate autophagy when overexpressed in mammalian cells (3). Mammalian Beclin-1 was originally isolated in a yeast two-hybrid screen for Bcl-2 interacting proteins and has been shown to interact with Bcl-2 and Bcl-xL but not with Bax or Bak (4). While Beclin-1 is generally ubiquitously expressed, it is monoallelically deleted in 40-75% of sporadic human breast and ovarian cancers (5). It is localized within cytoplasmic structures including the mitochondria, although overexpression of Beclin-1 reveals some nuclear staining and CRM1-dependent nuclear export (6). Beclin-1 -/- mice die early in embryogenesis and Beclin-1 +/- mice have a high incidence of spontaneous tumors. Stem cells from the null mice demonstrate an altered autophagic response although responses to apoptosis appeared normal (7). Overexpression of Beclin-1 in virally infected neurons *in vivo* resulted in significant protection against Sindbis virus-induced disease and neuronal apoptosis (4).

**Directions for Use:** CST recommends transfection with 100 nM Beclin-1 siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

**Quality Control:** Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

**Specificity/ Sensitivity:** Beclin-1 siRNA II will inhibit human and rat Beclin-1 expression.



Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® Beclin-1 siRNA I #6222 (+) or SignalSilence® Beclin-1 siRNA II (+), using Beclin-1 (D40C5) XP™ Rabbit mAb #3495 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The Beclin-1 (D40C5) XP™ Rabbit mAb confirms silencing of Beclin-1 expression, while the α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of Beclin-1 siRNA.

Entrez-Gene ID #8678  
Swiss-Prot Acc. #Q14457

**Storage:** Beclin-1 siRNA I is supplied in RNase-free water. Aliquot and store at -20°C.

Please visit [www.cellsignal.com](http://www.cellsignal.com) for a complete listing of recommended companion products.

### Background References:

- (1) Reggiori, F. and Klionsky, D.J. (2002) *Eukaryotic Cell* 1, 11-21.
- (2) Kametaka, S. et al. (1998) *J. Biol. Chem.* 273, 22284-22291.
- (3) Liang, X. H. et al. (1999) *Nature* 402, 672-676.
- (4) Liang, X. H. et al. (1998) *J. Virol.* 72, 8586-8596.
- (5) Aita, V. M. et al. (1999) *Genomics* 59, 59-65.
- (6) Liang, X. H. et al. (2001) *Cancer Res.* 61, 3443-3449.
- (7) Yue, Z. et al. (2003) *Proc. Natl. Acad. Sci. USA* 100, 15077-15082.